Sandoz CEO expects Ozempic biosimilars to enter Canadian market in Q1, Q2

Core Insights - Sandoz, a generic drug giant, anticipates the launch of unbranded versions of Novo Nordisk's diabetes drug Ozempic in Canada by the second quarter of next year following the expiration of a key patent [1] Company Summary - Sandoz is preparing to introduce generic alternatives to Ozempic, which is a popular diabetes medication produced by Novo Nordisk [1] Industry Summary - The expiration of the patent for Ozempic is expected to create opportunities for generic drug manufacturers like Sandoz to enter the market, potentially impacting the competitive landscape in the diabetes treatment sector [1]